NCT04807166View on ClinicalTrials.gov

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 24, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2027

Conditions
Ovarian NeoplasmsFallopian Tube NeoplasmsNeoplasms by SiteGenital Neoplasms, FemaleNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeCarcinoma, Ovarian EpithelialOvarian DiseasesGenital Diseases, FemaleEndocrine System DiseasesCarcinomaAnlotinibAngiogenesisAntineoplastic AgentsTyrosine Kinase Inhibitor
Interventions
DRUG

Drug: Anlotinib

Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle

DRUG

Drug: Carboplatin/Paclitaxel

Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1

Trial Locations (6)

Unknown

Huai'an First People's Hospital, Huai'an

Nanjing Drum Tower Hospital, Nanjing

Zhongda Hospital Southeast University, Nanjing

The First Affiliated Hospital of Soochow University, Suzhou

Affiliated Hospital of Jiangnan University, Wuxi

Yancheng No.1 People's Hospital, Yancheng

All Listed Sponsors
lead

Wenjun Cheng

OTHER